<DOC>
	<DOC>NCT00819195</DOC>
	<brief_summary>The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and Treg differentiation of naïve T cells.</brief_summary>
	<brief_title>Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Relapsingremitting (RR) MS patients (McDonald criteria) Ages 1855 Males and females EDSS score ≤5 No prior treatment with Copaxone Prior treatment with corticosteroids or interferonbeta (1a or 1b) is acceptable, provided there is a washout period of at least one month Treatment with Tysabri, Novantrone or cyclophosphamide Treatment with other immunomodulatory therapies (e.g. imuran, mycophenolate or methotrexate) Primaryprogressive (PP) and secondaryprogressive (SP) multiple sclerosis Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>relapsing-remitting</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>Copaxone</keyword>
	<keyword>glatiramer acetate</keyword>
	<keyword>MS</keyword>
</DOC>